第27届欧洲血液学年会（EHA）将于2022年6月9日~12日以线上+线下的形式召开，会议由欧洲血液学会主办。作为欧洲血液学领域规模最大的国际会议，每年都有来自全球100多个国家的10000余名专业人士与会，一起分享并探讨有关血液学的创新理念及最新的科学和临床研究成果。随着中国临床研究的快速发展，中国在世界血液学领域也发挥着日益重要的作用，在新冠疫情大背景下，更是为世界血液科医生提供了宝贵的患者管理经验。今年，中国专家有69篇Poster以及55篇ePoster入围EHA年会，让我们一起盘点一下吧。 2022 EHA 中国专家Poster汇总 1 摘要号：P322 题目：THERAPEUTIC EFFECT OF TARGETING CASEIN KINASE II / WDR5 AXIS IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA 报告人：葛峥 单位：东南大学附属中大医院 2 摘要号：P349 题目：CLONAL ARCHITECTURE DISSECTING AT SINGLE-CELL RESOLUTION REVEALS MECHANISMS OF CHEMOTHERAPY RESISTANCE AND RELAPSE IN T CELL ACUTE LYMPHOBLASTIC LEUKEMIA 报告人：Jingliao Zhang 单位：中国医学科学院血液病医院 3 摘要号：P358 题目：COMPREHENSIVE DIAGNOSTICS OF ACUTE LYMPHOBLASTIC LEUKEMIA BY WHOLE TRANSCRIPTOME RNA SEQUENCING 报告人：Jing Li 4 摘要号：P370 题目：EARLY RESULTS OF A SAFETY AND EFFICACY STUDY OF ALLOGENEIC TRUUCAR™ GC502 IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL) 报告人：黎诗琦 单位：解放军联勤保障部队902医院 5 摘要号：P378 题目：THE PROGNOSIS FACTORS OF CAR-T THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY B-ALL 报告人：胡星星 单位：陕西省人民医院 6 摘要号：P393 题目：SYNERGISTIC EFFECT OF EZH2 INHIBITOR WITH BCL2 INHIBITOR BY ENHANCING PIK3IP1 EXPRESSION IN ACUTE MYELOID LEUKEMIA 报告人：葛峥 单位：东南大学附属中大医院 7 摘要号：P407 题目：SYNERGISTIC EFFECT OF A NOVEL COMBINATION OF HDACI CHIDAMIDE WITH CLADRIBINE ON CELL PROLIFERATION ARREST AND APOPTOSIS IN ACUTE MYELOID LEUKEMIA BY TARGETING MYC/HDAC2 SIGNALING 报告人：葛峥 单位：东南大学附属中大医院 8 摘要号：P469 题目：CHEMORESISTANCE IN ACUTE MYELOID LEUKEMIA: A SINGLE-CELL RNA SEQUENCING APPROACH 报告人：Chieh-Lin Teng 单位：台中荣民总医院 9 摘要号：P486 题目：CD9 MARKS DIFFERENTIATION AND ANTI-TUMOR IMMUNITY IN PEDIATRIC ACUTE MYELOID LEUKEMIA 报告人：Yaqun Xu 单位：香港中文大学 10 摘要号：P488 题目：THZ1, A COVALENT CDK7 INHIBITOR, INDUCES APOPTOSIS IN ACUTE MYELOID LEUKEMIA CELLS AND EXERTS SYNERGISTIC ANTILEUKEMIA ACTIVITY WITH AZACITIDINE 报告人：张帅 单位：北京医院 11 摘要号：P516 题目：ADULT LANGERHANS CELL HISTIOCYTOSIS WITH THYROID GLAND INVOLVEMENT: CLINICAL PRESENTATION, GENOMIC ANALYSIS AND OUTCOME 报告人：蔡华聪 单位：北京协和医院 12 摘要号：P533 题目：SINGLE-CENTER PHASE 2 STUDY OF PD-1 INHIBITOR COMBINED WITH DNA DEMETHYLATION AGENT + CAG REGIMEN IN PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA: INTERIM ANALYSIS 报告人：高晓宁 单位：中国人民解放军总医院第五医学中心 13 摘要号：P549 题目：ANALYSIS OF THE CLINICAL SIGNIFICANCE AND PROGNOSTIC IMPACT OF TET2 SINGLE NUCLEOTIDE POLYMORPHISM I1762V IN PATIENTS WITH ACUTE MYELOID LEUKEMIA 报告人：吕晓东 单位：河南省肿瘤医院 14 摘要号：P560 题目：ANALYSIS OF GENE MUTATION SPECTRUM AND CORRELATION BETWEEN GENETIC ABNORMALITIES IN 207 PATIANTS WITH T(8; 21) AML 报告人：anbo Nie 15 摘要号：P588 题目：IMPROVED OUTCOME OF RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA BY ADDITION OF LIPOSOMAL ADRIAMYCIN TO CLAG CHEMOTHERAPY 报告人：姚浛 单位：陆军军医大学第二附属医院（新桥医院） 16 摘要号：P591 题目：PRELIMINARY RESULTS OF A PHASE I STUDY OF CLIFUTINIB, A HIGHLY SELECTIVE, POTENT ORAL FLT-3 INHIBITOR, IN PATINETS WITH FLT3-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA 报告人：金洁 单位：浙江大学附属第一医院 17 摘要号：P610 题目：SYNERGISTIC ACTIVITY OF FTO INHIBITOR FB23-2 WITH IBRUTINIB IN XENOGRAFT MURINE MODEL OF CHRONIC LYMPHOCYTIC LEUKEMIA 报告人：Xinting Hu 单位：山东省立医院 18 摘要号：P684 题目：PHASE 1 STUDY OF LP-108, A SELECTIVE BCL-2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA 报告人：徐卫 单位：江苏省人民医院 19 摘要号：P710 题目：CLINICAL STUDY ON THE RELATIONSHIP BETWEEN NON-ABL1 KINASE REGION MUTATION AND TKI DRUG RESISTANCE AND DISEASE PROGRESSION IN CHRONIC MYELOID LEUKEMIA 报告人：吕晓东 单位：河南省肿瘤医院 20 摘要号：P721 题目：PREDICTIVE SCORING SYSTEMS FOR MOLECULAR RESPONSES IN PERSONS WITH CHRONIC MYELOID LEUKEMIA RECEIVING INITIAL IMATINIB THERAPY 报告人：张小帅 单位：北京大学人民医院 21 摘要号：P722 题目：IS THE SECOND-GENERATION TYROSINE KINASE INHIBITOR A BETTER THERAPY THAN IMATINIB FOR PERSONS WITH CHRONIC MYELOID LEUKEMIA PRESENTING IN ACCELERATED-PHASE? 报告人：张小帅 单位：北京大学人民医院 22 摘要号：P733 题目：DHX9 HELICASE DYSFUNCTION CONTRIBUTES TO DISEASE PROGRESSION IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES 报告人：许峰 单位：上海市第六人民医院 23 摘要号：P736 题目：BCOR MUTATION REGULATES MYELODYSPLASTIC SYNDROMES PROGRESSION THROUGH REPRESSING AUTOPHAGY FLUX MEDIATED BY HDAC6 ACTIVATION 报告人：吴凌云 单位：上海市第六人民医院 24 摘要号：P753 题目：DYSFUNCTIONAL BONE MARROW ENDOTHELIAL PROGENITOR CELLS ARE INVOLVED IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES 报告人：Tong Xing 单位：北京大学人民医院 25 摘要号：P773 题目：THE ELEVATION OF RED BLOOD CELL DISTRIBUTION IS AN INDEPENDENT PROGNOSTIC FACTOR FOR JUVENILE MYELOMONOCYTIC LEUKEMIA 报告人：Weiru Liang 单位：中国医学科学院北京协和医学院 26 摘要号：P811 题目：A SINGLE CENTER HISTORICAL CONTROL STUDY OF ELTROMBOPAG ADDED TO IMMUNOSUPPRESSIVE THERAPY FOR SEVERE APLASTIC ANEMIA IN CHILDREN 报告人：Bixi Yang 单位：首都医科大学附属北京儿童医院 27 摘要号：P880 题目：OVEREXPRESSION OF PFKFB4 PROMOTES ADAPTATION TO HYPOXIC MICROENVIRONMENT IN MULTIPLE MYELOMA 报告人：Jie Yang 单位：东南大学附属中大医院 28 摘要号：P895 题目：DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (D-VD) VERSUS BORTEZOMIB AND DEXAMETHASONE (VD) ALONE IN CHINESE PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED ANALYSIS OF LEPUS 报告人：傅卫军 单位：上海长征医院 29 摘要号：P896 题目：DEVELOPMENT AND VALIDATION OF A FRAILTY PREDICTION MODEL MORE SUITABLE FOR MULTIPLE MYELOMA IN CHINESE PATIENTS: THE TM FRAILTY SCORE. 报告人：李娟 单位：中山大学附属第一医院 30 摘要号：P910 题目：DOES MINIMAL RESIDUAL DISEASE OF STEM CELL COLLECTION HAVE PROGNOSTIC IMPACT ON PATIENTS WITH MULTIPLE MYELOMA? 报告人：Xu Jingyu 单位：中国医学科学院血液病医院 31 摘要号：P953 题目：PHASE I STUDY OF TQB3602 CAPSULE, AN ORAL PROTEASOME INHIBITOR, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA 报告人：牛挺 单位：四川大学华西医院 32 摘要号：P974 题目：THE CLINICAL CHARACTERISTICS AND PROGNOSIS OF PATIENTS WITH PRIMARY PLASMA CELL LEUKEMIA (PPCL) UNDER THE NEW IWMG DEFINITION CRITERIA 报告人：唐文娇 单位：中国医学科学院血液病医院 33 摘要号：P976 题目：BENDAMUSTINE-POMALIDOMIDE-DEXAMETHASONE (BPD) FOR RELAPSED AND/OR REFRACTOR MULTIPLE MYELOMA WITH EXTRAMEDULLARY DISEASE 报告人：钟玉萍 单位：青岛市市立医院 34 摘要号：P1004 题目：EFFECT AND MOLECULAR MECHANISM OF TQ05105, A NOVEL SMALL MOLECULE INHIBITOR OF JAK2 IN MYELOPROLIFERATIVE NEOPLASM 报告人：Wenjun Zhang 单位：中国医学科学院血液病医院 35 摘要号：P1067 题目：PHASE 2 STUDY OF ORAL THALIDOMIDE-CYCLOPHOSPHAMIDE-DEXAMETHASONE FOR RECURRENT/REFRACTORY ADULT LANGERHANS CELL HISTIOCYTOSIS 报告人：Ji-nuo Wang 单位：北京协和医院 36 摘要号：P1072 题目：NATURAL HISTORY OF JUVENILE MYELOMONOCYTIC LEUKEMIA 报告人：Wenyu Yang 单位：中国医学科学院血液病医院 37 摘要号：P1173 题目：CLINICAL APPLICABILITY OF TARGETED NEXT-GENERATION SEQUENCING FOR PRECISION MEDICINE IN DIFFUSE LARGE B CELL LYMPHOMA 报告人：黄德鸿 单位：重庆大学附属肿瘤医院 38 摘要号：P1192 题目：ASIA SUBPOPULATION ANALYSIS FROM THE PHASE III POLARIX TRIAL 报告人：宋玉琴 单位：北京大学肿瘤医院 39 摘要号：P1199 题目：MACHINE-LEARNING ALGORITHM TO DETECTION OF LYMPHOMA WITH BONE MARROW INVOLVEMENT VIA FDG-18 PET/CT 报告人：Cho-Hao Lee 单位：三军总医院 40 摘要号：P1201 题目：ZANUBRUTINIB PLUS RCHOP(ZR-CHOP) REGIMEN ACHIEVES HIGH COMPLETE RESPONSE RATE IN THE TREATMENT OF NEWLY-DIAGNOSED DOUBLE-EXPRESSION DIFFUSE LARGE B CELL LYMPHOMA 报告人：李增军 单位：山东省肿瘤医院 41 摘要号：P1205 题目：PROGNOSTIC ROLE OF TUMOR P53 MUTATION IN DIFFUSE LARGE B CELL LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS 报告人：马骥 单位：山东省肿瘤医院 42 摘要号：P1206 题目：GASTROINTESTINAL BLEEDING SIGNIFICANTLY REDUCED THE EFFICACY AND SURVIVAL OF CD19 CAR-T CELL THERAPY IN PATIENTS WITH GASTROINTESTINAL TRACT INVOLVEMENT OF REFRACTORY/RELAPSED B-CELL LYMPHOMA 报告人：胡凯 单位：北京高博博仁医院 43 摘要号：P1216 题目：ZANUBRUTINIB PLUS R-CHOP(RI-CHOP) AS THE TREATMENT FOR DOUBLE EXPRESSION OF MYC/BCL2 IN PATIENTS WITH DIFFUSED LARGE B-CELL LYMPHOMA 报告人：任柯星 单位：四川大学华西医院 44 摘要号：P1218 题目：FIRST-IN-HUMAN STUDY OF CD19/BCMA DUAL-TARGETING FAST CAR-T GC012F FOR PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA 报告人：陈新锋 单位：郑州大学第一附属医院 45 摘要号：P1236 题目：EFFICACY AND TOXICITY FOR CD7 CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY T-CELL LYMPHOMA 报告人：胡凯 单位：北京高博博仁医院 46 摘要号：P1237 题目：PRELIMINARY RESULTS OF A PHASE Ⅱ STUDY OF ZANUBRUTINIB COMBINED WITH IMMUNOCHEMOTHERAPY IN PATIENTS WITH CD79A/CD79B-MUTANT DIFFUSE LARGE B-CELL LYMPHOMA 报告人：姚志华 单位：河南省肿瘤医院 47 摘要号：P1238 题目：EFFICACY ANALYSIS OF PEGASPARGASE, GEMCITABINE, OXALIPLATIN, DEXAMETHASONE COMBINED WITH TISLELIZUMAB IN FIRST-LINE TREATMENT OF PLASMA EBV-DNA POSITIVE EXTRANODAL NK/T CELL LYMPHOMA 报告人：朱尊民 单位：河南省人民医院 48 摘要号：P1240 题目：ANTI-PD-1-ANTIBODY (TISLELIZUMAB) COMBINED WITH DEACETYLASE INHIBITOR (CHIDAMIDE), LENALIDOMIDE AND ETOPOSIDE FOR THE TREATMENT OF REFRACTORY/RELAPSED EXTRANODAL NATURAL KILLER/T CELL LYMPHOMA, NASAL 报告人：张蕾 单位：郑州大学第一附属医院 49 摘要号：P1241 题目：THE INCIDENCE AND SURVIVAL OUTCOMES OF PATIENTS WITH PRIMARY GASTRIC T-CELL LYMPHOMA: A SEER POPULATION-BASED STUDY 报告人：张旻玥 单位：上海交通大学医学院附属仁济医院 50 摘要号：P1242 题目：ZANUBRUTINIB AND RITUXIMAB REGIMEN COMBINED WITH INTRAVITREAL METHOTREXATE FOLLOWED BY ZANUBRUTINIB MAINTENANCE FOR TREAT-NAIVE PRIMARY VITREORETINAL LYMPHOMA: A PROSPECTIVE PHASE II STUDY 报告人：张炎 单位：北京协和医院 51 摘要号：P1311 题目：GRANULOCYTE COLONY-STIMULATING FACTOR MOBILIZATION FACILITATES ANTI-GRAFT-VERSUS-HOST DISEASE AND GRAFT-VERSUS-LEUKEMIA EFFECTS OF MUCOSA-ASSOCIATED INVARIANT T CELLS THROUGH DISTINCT FUNCTIONAL SUBSE 报告人：高梦鸽 单位：北京大学人民医院 52 摘要号：P1386 题目：A REVIEW OF HEMATOPOIETIC CELL TRANSPLANTATION IN TAIWAN: DATA AND TRENDS DURING 2009–2018 报告人：Yu-Hung Wang 单位：国立台湾大学医学院附设医院 53 摘要号：P1393 题目：HIGHER DOSE OF CD34+ CELLS PROMOTES EARLY RECONSTITUTION OF NATURAL KILLER CELLS AND IS ASSOCIATED WITH BETTER OUTCOMES AFTER UNMANIPULATED HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MYELOID MALIGNAN 报告人：Fei Zhao 单位：中国医学科学院血液病医院 54 摘要号：P1394 题目：DIFFERENT DOSES OF ANTITHYMOCYTE GLOBULIN (ATG) AS PART OF THE PREPARATIVE REGIMEN INHEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) 报告人：熊敏 单位：北京陆道培医院 55 摘要号：P1364 题目：HLA MISMATCHED UNRELATED STEM CELL TRANSPLANTATION USING ANTITHYMOCYTE GLOBULIN IS A SUITABLE ALTERNATIVE FOR PATIENTS LACKING HLA-MATCHED UNRELATED DONORS: SINGLE CENTER LONG-TERM FOLLOW-UP DATA ANAL 报告人：高蕾 单位：陆军军医大学第二附属医院（新桥医院） 56 摘要号：P1370 题目：EFFECTS OF CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL FROM HEALTHY DONORS ON RECIPIENTS AFTER TRANSPLANTATION AND RELATED RESEARCH 报告人：Biao Shen 单位：中国医学科学院血液病医院 57 摘要号：P1385 题目：THE GUIDING SIGNIFICANCE OF IMMUNE CELL SUBSET MONITORING IN IMMUNE RECONSTITUTION IN PATIENTS WITH CAR-T BRIDGED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION 报告人：赵玮 单位：北京陆道培医院 58 摘要号：P1392 题目：MACHINE LEARNING ALGORITHM AS A PROGNOSTIC TOOL FOR VENOUS THROMBOEMBOLISM IN ALLOGENIC TRANSPLANT PATIENTS 报告人：邓睿歆 单位：北京大学人民医院 59 摘要号：P1422 题目：IN VIVO G-CSF TREATMENT ACTIVATES THE GR-SOCS1 AXIS TO SUPPRESS IFN-Γ SECRETION BY NATURAL KILLER CELLS 报告人：Xunhong Cao 单位：北京大学人民医院 60 摘要号：P1440 题目：BTK INHIBITORS IMPROVE CART19 CELL THERAPY BY MODULATING IMMUNE SYSTEM 报告人：梅恒 单位：华中科技大学同济医学院附属协和医院 61 摘要号：P1441 题目：SINGLE-CELL TRANSCRIPTOMIC CHARACTERIZATIONS OF BONE MARROW MONONUCLEAR CELLS AND CAR-T PRODUCTS ASSOCIATED WITH EFFICACY AND TOXICITY IN B-ALL PATIENTS 报告人：梅恒 单位：华中科技大学同济医学院附属协和医院 62 摘要号：P1643 题目：EFFICACY OF RECOMBINANT HUMANTHROMBOPOIETIN ON CHILDREN IMMUNE THROMBOCYTOPENIA AND ITS INFLUENCING FACTORS 报告人：马静瑶 单位：首都医科大学附属北京儿童医院 63 摘要号：P1650 题目：METABOLIC ABNORMALITY AND GLUCOCORTICOID RECEPTOR MODULATION OF MYELOID-DERIVED SUPPRESSOR CELLS IN IMMUNE THROMBOCYTOPENIA PATIENTS AND AN ACTIVE MURINE MODEL 报告人：Shuwen Wang 单位：山东大学 64 摘要号：P1651 题目：HDAC3 RS2530223 IS ASSOCIATED WITH INCREASED SUSCEPTIBILITY AND SEVERITY OF PRIMARY IMMUNE THROMBOCYTOPENIA 报告人：Shuwen Wang 单位：山东大学 65 摘要号：P1652 题目：MACHINE-LEARNING-BASED MORTALITY PREDICTION OF ICH IN ADULTS WITH ITP: A NATIONWIDE REPRESENTATIVE MULTICENTRE STUDY 报告人：Shan Chong 单位：北京大学人民医院 66 摘要号：P1653 题目：CLINICAL EFFICACY AND SAFETY OF SWITCHING ELTROMBOPAG AND RH-TPO IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA DURING THE COVID-19 PANDEMIC 报告人：Xuan Cai 单位：北京大学人民医院 67 摘要号：P1654 题目：COMPLEMENT ACTIVATION REGULATES PLATELET HOMEOSTASIS BY ARRESTING THE ANTI-INFLAMMATORY EFFECTS OF INTERLEUKIN-35 IN IMMUNE THROMBOCYTOPENIA 报告人：Yejun Wu 单位：北京大学血液研究所 68 摘要号：P1655 题目：PERSONALIZED MACHINE-LEARNING-BASED PREDICTION FOR CRITICAL IMMUNE THROMBOCYTOPENIA BLEEDS: A NATIONWIDE DATA STUDY 报告人：Zhuo-Yu An 单位：北京大学人民医院 69 摘要号：P1662 题目：OPTIMIZED PROPHYLAXIS BASED ON INDIVIDUALIZED TARGET TROUGH FVIII LEVEL IN PEDIATRIC PATIENTS WITH SEVERE HEMOPHILIA A 报告人：Kun Huang 单位：首都医科大学附属北京儿童医院 2022 EHA 中国专家ePoster汇总 1 摘要号：P364 题目：DONOR-DERIVED CD19 CAR-T CELLS AND CHEMOTHERAPY PLUS DONOR LYMPHOCYTE INFUSION IN THE TREATMENT OF RECURRENT CD19+ B-ALL AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION 报告人：张曦 单位：陆军军医大学第二附属医院（新桥医院） 2 摘要号：P377 题目：GENETIC CHARACTERISTICS AND CD7-CAR-T THERAPY OF TRAD::MYC TRANSLOCATION POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS 报告人：刘红星 单位：河北燕达陆道培医院 3 摘要号：P480 题目：NKG2D-MEDIATED ANTI-TUMOR IMMUNITY CONTRIBUTES TO THE FAVORABLE PROGNOSIS IN APL 报告人：王怀宇 单位：西安交通大学第一附属医院 4 摘要号：P554 题目：GILTERITINIB VERSUS SALVAGE CHEMOTHERAPY FOR RELAPSED/REFRACTORY FLT3-MUTATED ACUTE MYELOID LEUKEMIA: A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL TRIAL IN ASIA 报告人：王建祥 单位：中国医学科学研血液病医院（天津血研所） 5 摘要号：P625 题目：SINGLE-CELL RNA SEQUENCING REVEALS THE HETEROGENEITY OF TUMOR CELLS AND IMMUNE MICROENVIRONMENT IN RICHTER SYNDROME AND ACCELERATED CLL 报告人：Yeqin Sha 单位：南京医科大学第一附属医院 6 摘要号：P734 题目：DOWN-REGULATION OF RING1 AND YY1 BINDING (RYBP) LEADS TO EPIGENETIC OVEREXPRESSION OF ANTI-APOPTOTIC PROTEIN BCL2 IN MYELODYSPLASTIC SYNDROMES 报告人：许峰 单位：上海市第六人民医院 7 摘要号：P749 题目：PROGNOSTIC SIGNIFICANCE OF SERIAL CIRCULATING TUMOR DNA STATUS POST TREATMENT IN MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA 报告人：佟红艳 单位：浙江大学附属第一医院 8 摘要号：P759 题目：CORRELATION ANALYSIS OF DNA METHYLATION LEVEL AND CLINICAL CHARACTERISTICS IN JMML PATIENTS 报告人：Yuli Cai 单位：中国医学科学院血液病医院 9 摘要号：P780 题目：COMBINATION THERAPY OF ELTROMBOPAG AND CYCLOSPORINE A CAN IMPROVE HEMATOPOIESIS IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROME 报告人：Luxi Song 单位：上海市第六人民医院 10 摘要号：P786 题目：ANTI-PD-1 ANTIBODY (SINTILIMAB) PLUS DECITABINE AS FIRST LINE TREATMENT FOR PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME（MDS）: PRELIMINARY RESULTS FROM A SINGLE-ARM, OPEN-LABEL, PHASE II STUDY 报告人：Jing Wang 单位：北京大学人民医院 11 摘要号：P789 题目：ANALYSIS OF THE CLINICAL FEATURES, PROGNOSIS AND GENE MUTATIONS IN PRIMARY MYELODYSPLASTIC SYNDROME PATIENTS WITH MYELOFIBROSIS 报告人：Gaixiang Xu 单位：浙江大学附属第一医院 12 摘要号：P790 题目：THE EXPRESSION LEVEL OF WT1 MRNA IN PATIENTS WITH IDIOPATHIC CYTOPENIA OF UNDETERMINED SIGNIFICANCE (ICUS) PROGRESSING TO MYELODYSPLASTIC SYNDROME (MDS) 报告人：Xingnong Ye 单位：浙江大学附属第一医院 13 摘要号：P796 题目：ENRICHED CD16+ MONOCYTES DRIVE T LYMPHOCYTES CELL RESPONSES IN APLASTIC ANEMIA 报告人：Meili Ge 单位：中国医学科学院血液病医院 14 摘要号：P820 题目：PREDICTING RESPONSE TO RABBIT ATG-BASED INTENSIVE IMMUNOSUPPRESSIVE THERAPY COMBINED WITH ELTROMBOPAG IN CHINESE ADULT PATIENTS WITH SEVERE APLASTIC ANEMIA 报告人：何广胜 单位：南京医科大学第一附属医院 15 摘要号：P823 题目：THE INCIDENCE, OUTCOMES, AND RISK FACTORS OF SECONDARY POOR GRAFT FUNCTION IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACQUIRED APLASTIC ANEMIA 报告人：Fan Lin 单位：北京大学血液病研究所 16 摘要号：P878 题目：HIGH MUTATIONAL BURDEN OF CHROMATIN MODIFYING GENES DEFINES A RELATIVELY INDOLENT SUBGROUP OF PLASMA CELL DYSCRASIAS 报告人：Xuezhu Wang 单位：北京协和医院 17 摘要号：P882 题目：IDENTIFICATION OF M7G RNA METHYLATION REGULATORS AND M7G-RELATED GENES IN MULTIPLE MYELOMA 报告人：Manya Yu 单位：山东中医药大学 18 摘要号：P883 题目：TARGETING CALCINEURIN/NFATC1 SIGNALING SENSITIZES PROTEASOME INHIBITION TREATMENT IN MULTIPLE MYELOMA 报告人：Jinglin Zhang 单位：香港中文大学 19 摘要号：P903 题目：DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE IN NEWLY DIAGNOSED PATIENTS WITH MAYO 2004 STAGE 3 LIGHT-CHAIN AMYLOIDOSIS: A PROSPECTIVE PHASE 2 STUDY 报告人：Ya-juan Gao 单位：北京协和医院 20 摘要号：P909 题目：RENAL RESPONSE OF POMALIDOMIDE WITH BORTEZOMIB AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH RENAL IMPAIRMENT 报告人：高文 单位：首都医科大学附属北京朝阳医院 21 摘要号：P920 题目：EFFECTIVENESS AND SAFETY OF SELINEXOR-BASED REGIMEN IN THE TREATMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A MULTICENTER REAL-WORLD STUDY FROM CHINA 报告人：李娟 单位：中山大学第一附属医院 22 摘要号：P927 题目：CLINICAL CHARACTERISTICS, SURVIVAL OUTCOMES AND PROGNOSIS IN 123IMMUNOGLOBULIN D MULTIPLE MYELOMA PATIENTS: A RETROSPECTIVE SINGLE-CENTER 报告人：Jiahui Liu 单位：中国医学科学院血液病医院 23 摘要号：P944 题目：A PHASE I STUDY OF C-CAR088, A NOVEL HUMANIZED ANTI-BCMA CAR T CELL THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA 报告人：Xiaoyan Qu 单位：南京医科大学第一附属医院 24 摘要号：P969 题目：COMPARISON OF VENOUS THROMBOEMBOLISM INCIDENCE IN MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE-BASED REGIMENS WITH RIVAROXABAN OR ASPIRIN THROMBOPROPHYLAXIS 报告人：Siyuan Cui 单位：山东中医药大学附属医院 25 摘要号：P970 题目：SAFETY AND EFFICACY OF BCMA-CAR-T IMMUNE CELLS DERIVED FROM CORD BLOOD IN THE TREATMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA 报告人：Ying Gao 单位：陕西省人民医院 26 摘要号：P1047 题目：REAL-WORLD SAFETY OF RUXOLITINIB IN PATIENTS WITH INTERMEDIATE OR HIGH RISK OF PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS IN CHINA 报告人：肖志坚 单位：中国医学科学院血液病医院 27 摘要号：P1090 题目：CAMRELIZUMAB (CAM) COMBINED WITH GEMOX CHEMOTHERAPY RESULTS IN HIGH COMPLETE METABOLIC RESPONSE RATES IN RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA (CHL): A PHASE II TRIAL 报告人：Yan Xie 单位：北京大学肿瘤医院 28 摘要号：P1106 题目：PRELIMINARY RESULTS OF A PHASE 1 STUDY OF NOVEL BCL-2 INHIBITOR LISAFTOCLAX (APG-2575) IN CHINESE PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMAS (NHLS) 报告人：Mingyuan Sun 单位：中国医学科学院血液病医院 29 摘要号：P1118 题目：PROGNOSTIC SIGNIFICANCE OF ABSOLUTE MONOCYTE COUNT AND LYMPHOCYTE TO MONOCYTE RATIO IN MUCOSA-ASSOCIATED LYMPHOID TISSUE (MALT) LYMPHOMA 报告人：Yue Li 单位：南京医科大学第一附属医院 30 摘要号：P1120 题目：THE EFFICACY AND SAFETY OF ZANUBRUTINIB AND DEXAMETHASONE IN SYMPTOMATIC WALDENSTROM MACROGLOBULINNEMIA 报告人：陈文明 单位：首都医科大学附属北京朝阳医院 31 摘要号：P1185 题目：ANTITUMOR ACTIVITY AND SAFETY OF ZANUBRUTINIB COMBINED WITH R-CHOP REGIMEN IN THE TREATMENT OF NEWLY DIAGNOSED NON-GCB DLBCL WITH EXTRANODAL INVOLVEMENT: A PROSPECTIVE PHASE II STUDY. 报告人：C. Li 单位：苏州大学第一附属医院 32 摘要号：P1219 题目：ZANUBRUTINIB, LENALIDOMIDE PLUS R-CHOP (ZR2-CHOP) AS THE FIRST-LINE TREATMENT FOR NON-GCB DIFFUSED LARGE B-CELL LYMPHOMA (DLBCL) 报告人：朱华渊 单位：南京医科大学第一附属医院 33 摘要号：P1223 题目：PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A RETROSPECTIVE STUDY OF THE ZRMA REGIMEN（ZANUBRUTINIB, RITUXIMAB, METHOTREXATE AND CYTARABINE） 报告人：Youhong Tang 单位：中南大学湘雅医院 34 摘要号：P1234 题目：REAL-WORLD EXPERIENCE OF OUTCOMES WITH GLOFITAMAB SALVAGE THERAPY FOR RELAPSE/REFRACTORY B-CELL LYMPHOMA IN TAIWAN: MINIMAL SAFETY CONCERN WITH HEPATITIS B REACTIVATION 报告人：Shang-Ju Wu 单位：国立台湾大学医学院副设医院 35 摘要号：P1235 题目：GENOTYPING ON CIRCULATING TUMOR DNA IMPROVES MUTATION DETECTION RATE IN HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA 报告人：徐卫 单位：南京医科大学第一附属医院 36 摘要号：P1243 题目：RUXOLITINIB COMBINED WITH DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: INTERIM ANALYSIS OF A PROSPECTIVE, SINGLE-CENTER, SINGLE-ARM, PHASE 2 CLINICAL TRIAL 报告人：De Zhou 单位：浙江大学附属第一医院 37 摘要号：P1280 题目：TARGETED INHIBITION OF DHODH IS SYNERGISTIC WITH BCL2 BLOCKADE IN LYMPHOMA WITH CONCURRENT MYC AND BCL2 REARRANGEMENT 报告人：闫晓菁 单位：中国医科大学第一附属医院 38 摘要号：P1305 题目：HSA_CIRC_0001599 REGULATES IL18 LEVELS IN AGVHD VIA CERNA MECHANISM 报告人：Mengting Xia 单位：山东中医药大学 39 摘要号：P1315 题目：ENGRAFTMENT AND MOBILIZATION OF HUMAN HEMATOPOIETIC STEM/PROGENITOR CELLS ALIGNS WITH DYNAMIC OSCILLATION OF TETRASPANIN CD9 报告人：Wing Hei Ng 单位：香港中文大学 40 摘要号：P1327 题目：RUXOLITINIB COMBINED WITH GLUCOCORTICOID IN THE FIRST-LINE TREATMENT OF GRAFT-VERSUS-HOST DISEASE IN CHILDREN: A SINGLE CENTER RETROSPECTIVE STUDY 报告人：Kai Chen 单位：上海市儿童医院 41 摘要号：P1341 题目：HAPLO-CORD VS HAPLOIDENTICAL TRANSPLANT IN 49 CHILDREN – A RETROSPECTIVE SINGLE CENTER ANALYSIS 报告人：Pan Fu 单位：上海市儿童医院 42 摘要号：P1375 题目：SECOND PRIMARY MALIGNANCY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION 报告人：Tran-Der Tan 单位：中国台湾顾氏基金孙中山癌症中心 43 摘要号：P1388 题目：A SINGLE-ARM, PROSPECTIVE MULTICENTER CLINICAL STUDY OF RELATED HLA HAPLOIDENTICAL PERIPHERAL BLOOD HEMATOPOIETIC STEM CELL TRANSPLANTATION WITHOUT IN VITRO T-CELL DEPLETION FOR HEMATOLOGICAL MALIGNAN 报告人：Ming Jiang 单位：新疆医科大学第一附属医院 44 摘要号：P1390 题目：THE EFFICACY AND SAFETY OF MODIFIED MELPHALAN AND BUSULFAN-BASED REGIMEN FOR ALLOGENEIC TRANSPLANTATION IN REFRACTORY/RELAPSED AML PATIENTS 报告人：Shulian Chen 单位：中国医学科学院血液病医院 45 摘要号：P1391 题目：COMPARISON OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION FOR ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA IN FIRST COMPLETE REMISSION 报告人：Rongli Zhang 单位：中国医学科学院血液病医院 46 摘要号：P1452 题目：THE PRELIMINARY SAFETY AND EFFICACY STUDY OF SC-U02, A NON-VIRAL GENOME TARGETING, ANTI-CD19 UNIVERSAL CAR-T PRODUCT, IN RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS 报告人：Li Liu 单位：第四军医大学唐都医院 47 摘要号：P1465 题目：INITIAL SAFETY AND EFFICACY STUDY OF RM-001, AUTOLOGOUS HBG1/2 PROMOTER-MODIFIED CD34+ HEMATOPOIETIC STEM AND PROGENITOR CELLS, IN TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA 报告人：Li Wang 单位：解放军第923医院 48 摘要号：P1603 题目：CLINICAL OBSERVATION OF PATHOGEN MICROBIAL NEXT-GENERATION SEQUENCING ASSISTED IN INFECTION DIAGNOSIS AND TREATMENT OF PATIENTS WITH HEMATOLOGICAL TUMORS 报告人：张曦 单位：陆军军医大学第二附属医院(新桥医院) 49 摘要号：P1604 题目：DISTRIBUTION AND ANTIBIOTIC RESISTANCE PROFILE OF PATHOGENIC MICROORGANISMS CAUSING NOSOCOMIAL INFECTION IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION 报告人：Yimei Feng 单位：陆军军医大学第二附属医院(新桥医院) 50 摘要号：P1617 题目：CLINICAL SIGNIFICANCE OF CYTOMEGALOVIRUS DRUG RESISTANCE GENE MUTATIONS IN CYTOMEGALOVIRUS INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION 报告人：Jingjing Wen 单位：电子科技大学医学院附属绵阳医院 51 摘要号：P1634 题目：EFFICACY AND SAFETY OF ELTROMBOPAG IN THE TREATMENT OF CHRONIC HEPATITIS B VIRUS INFECTION PATIENTS WITH THROMBOCYTOPENIA（HBV-TP）: A PROSPECTIVE, MULTI-CENTER, SINGLE ARM, PHASE II TRAIL 报告人：Yunfei Chen 单位：中国医学科学院血液病医院 52 摘要号：P1641 题目：ELTROMBOPAG TREATMENT, OUTCOMES AFTER DISCONTINUATION IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA, AND EXPLORATION OF POTENTIAL PREDICTIVE FACTORS: A REAL-WORLD CLINICAL EXPERIENCE 报告人：Xiaofan Liu 单位：中国医学科学院血液病医院 53 摘要号：P1670 题目：LONG TERM SAFETY AND EFFICACY OF RECOMBINANT HUMAN COAGULATION FACTOR VIII (SCT800) IN PREVIOUSLY TREATED PATIENTS WITH SEVERE HEMOPHILIA A 报告人：Feng Xue 单位：中国医学科学院血液病医院 54 摘要号：P1716 题目：REGULAR HOSPITAL VISITS IMPROVE THE PROGNOSIS OF MULTIPLE MYELOMA PATIENTS 报告人：Xiaozhe Li 单位：中山大学附属第一医院 55 摘要号：P1737 题目：QUALITY OF LIFE IN CHILDREN WITH BETA-THALASSEMIA MAJOR: A CROSS-SECTIONAL STUDY IN CHINA 报告人：Zhen Song 单位：中国医学科学院血液病医院 注：排名不分先后，按照摘要号进行，如有遗漏，请给我们留言~
正文
p910（2022 EHA ）
由于无法甄别是否为投稿用户创作以及文章的准确性,本站尊重并保护知识产权，根据《信息网络传播权保护条例》，如我们转载的作品侵犯了您的权利,请在一个月内通知我们，请将本侵权页面网址发送邮件到，我们会做删除处理。
还没有评论，来说两句吧...